Study explorer (study characteristics and results) method abbreviations pdf   xlsx

display ongoing studies
Study Ref. Design studied treatmentcontrol treatmentpatientsstudy risk of biassample sizes Results deaths Eclinical improvement Edeath or ventilation E

COVID 19 hospitalized meta-analysis

RCTsarilumabstandard of careCOVID 19 hospitalizedsome concern
68/80 inconclusive -37% 11%

COVID-19 severe or critically meta-analysis

Lescure (Sarilumab 200mg)
RCTsarilumab low dose (200mg)placeboCOVID-19 severe or criticallysome concern
161/86 inconclusive 21% 3%
Lescure (Sarilumab 400mg)
RCTsarilumabplaceboCOVID-19 severe or criticallysome concern
173/86 inconclusive
Lescure (Sarilumab 400mg)
RCTsarilumab high dose (400mg)placeboCOVID-19 severe or criticallysome concern
173/86 inconclusive -3%
2 studies excluded by filtering options (1 RCT / 1 OBS)

PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).